These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083 [TBL] [Abstract][Full Text] [Related]
10. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529 [TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921 [TBL] [Abstract][Full Text] [Related]
13. Melatonin-vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat. Helmi YY; Papenkordt N; Rennar G; Gbahou F; El-Hady AK; Labani N; Schmidtkunz K; Boettcher S; Jockers R; Abdel-Halim M; Jung M; Zlotos DP Arch Pharm (Weinheim); 2023 Sep; 356(9):e2300149. PubMed ID: 37339785 [TBL] [Abstract][Full Text] [Related]
14. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197 [TBL] [Abstract][Full Text] [Related]
15. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. Pojani E; Barlocco D Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816 [TBL] [Abstract][Full Text] [Related]
16. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Duvic M; Dimopoulos M Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693 [TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. Marek L; Hamacher A; Hansen FK; Kuna K; Gohlke H; Kassack MU; Kurz T J Med Chem; 2013 Jan; 56(2):427-36. PubMed ID: 23252603 [TBL] [Abstract][Full Text] [Related]
19. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors. Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]